GRAVITON
Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases. TDI01, a highly selective, potent inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) is currently being studied in the United States for the treatment of idiopathic pulmonary fibrosis (IPF). Graviton anticipates entering human clinical studies in the U.S. in 2021.
GRAVITON
Industry:
Biotechnology Therapeutics
Founded:
2020-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.graviton.bio
Status:
Active
Contact:
+1 332-400-0444
Email Addresses:
[email protected]
Total Funding:
3.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Wordpress Plugins Nginx Microsoft Exchange Online
Similar Organizations
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Official Site Inspections
http://www.graviton.bio
- Host name: web2.axxiem.com
- IP address: 34.230.198.252
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
